

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,334
				Filing Date	October 27, 2005
				First Named Inventor	Mikhail I. Papisov
				Art Unit	1626
				Examiner Name	Chu, Yong Liang
Sheet	1	of	3	Attorney Docket Number	0492479-0041 (MGH 2170 US)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-5,075,222	12-24-1991	Hannum et al.	
	A2*	US-5,582,172	12-10-1996	Papisov et al.	
	A3*	US-5,624,803	04-29-1997	Noonberg et al.	
	A4*	US-5,811,510	09-22-1998	Papisov	
	A5*	US-5,817,343	10-06-1998	Burke	
	A6*	US-5,824,784	10-20-1998	Kinstler et al.	
	A7*	US-5,863,990	01-26-1999	Papisov	
	A8*	US-5,958,398	09-28-1999	Papisov	
	A9*	US-6,048,837	04-11-2000	Friedman et al.	
	A10*	US-6,057,431	05-02-2000	Ishihara et al.	
	A11*	US-6,294,170	09-25-2001	Boone et al.	
	A12*	US-20020082362	06-27-2002	Brocchini et al.	
	A13*	US-20040105840	06-03-2004	Kinstler et al.	
	A14*	US-6,822,086	11-23-2004	Papisov	
	A15*	US-20050169968	08-04-2005	Elmaleh et al.	
	A16*	US-20060019911	01-26-2006	Papisov	
	A17*	US-20060069230	03-30-2006	Papisov	
	A18*	US-7,160,924	01-09-2007	Kinstler et al.	
	A19*	US-20070190018	08-16-2007	PAPISOV	
	A20*	US-7,270,808	09-18-2007	Cheng et al.	
	A21*	US-20080019940	01-24-2008	Papisov	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP-0280474-A2	08-31-1988	Johnson Matthey Inc		
	B2	EP-0325270-A2	07-26-1989	Green Cross Corp		
	B3	WO-9605309-A2	02-22-1996	Univ Rockefeller et al.		
	B4	WO-9640912-A1	12-19-1996	Amgen Inc		
	B5	WO-9930561-A1	06-24-1999	Nexstar Pharmaceuticals Inc		
	B6	WO-0107486-A1	02-01-2001	Polygene Ltd et al.		
	B7	WO-0110468-A2	02-15-2001	Gen Hospital Corp et al.		
	B8	WO-03059988-A2	07-24-2003	Gen Hospital Corp et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
4597783v 1			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/521,334	
			Filing Date	October 27, 2005	
			First Named Inventor	Mikhail I. Papisov	
			Art Unit	1626	
			Examiner Name	Chu, Yong Liang	
Sheet	2	of	3	Attorney Docket Number	0492479-0041 (MGH 2170 US)

C1	Conover, C. et al. Physiological Effect of Polyethylene Glycol Conjugation on Stroma-Free Bovine Hemoglobin in the Conscious Dog After Partial Exchange Transfusion, Artificial Organs, Vol. 21, No. 5, 1997, pp 369-378
C2	Endo et al. Nature of Linkage and Mode of Action of Methotrexate Conjugated with Antitumor Antibodies: Implications for Future Preparation of Conjugates. Cancer Research. (1988), 48, p. 3330-3335
C3	Feng et al. Bioorg. Med. Chem. Lett. (2002) 12, pp. 3301-3303
C4	Gao Q. et al. Drug-induced DNA repair: X-ray structure of a DNA-ditercalinium complex Proc. Natl. Acad. Sci. USA Vol. 88, pp 2422-2426, March 1991 Biochemistry
C5	Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205-213
C6	Maeda, H et al. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 1992, 3:351-362
C7	Matysiak S. Acetal Oligonucleotide Conjugates In Antisense Strategy Nucleosides & Nucleotides, 16(5&6), pp 855-861 (1997)
C8	Papisov M.I. et al. Semisynthetic Hydrophilic Polyals Biomacromolecules 2005, vol. 6, pp 2659-2670
C9	Papisov, M et al. Fully biodegradable hydrophilic polyals (polyacetals and polyketals). 29th Int. Symp. on Controlled Release of Bioactive Materials, 2002, Seoul, Korea. Controlled Release Society, Deerfield, IL, 2002; paper # 465
C10	Papisov, M. (2001) Acyclic polyacetals from polysaccharides. (Biopolymers from polysaccharides and agroproteins), ACS Symposium Series 786, pp. 301-314
C11	Papisov, M. et al (1996) A long-circulating polymer with hydrolyzable main chain. 23-rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, 1996; Controlled Release Society, Deerfield, IL.; 107-108
C12	Papisov, M. et al. Fully biodegradable hydrophilic polyacetals for macromolecular radiopharmaceuticals. 49-th Annual Meeting of The Society of Nuclear Medicine, Los Angeles, CA, 2002. J. Nuc. Med. 2002, 43:5 (Supplement) p. 377P (abstract)
C13	Papisov, M. et al. Hydrophilic Polyals: Biomimetic Biodegradable Stealth Materials for Pharmacology and Bioengineering. Proceedings of 226th Natl. Meeting of American Chemical Society, New York, NY, 2003
C14	Papisov, MI et al. (1998) Model cooperative (multivalent) vectors for drug targeting. 25th Int. Symp. on Controlled Release of Bioactive Materials, 1998, Las Vegas, Nevada, USA; Controlled Release Society, Deerfield, IL, 170-171
C15	Papisov, MI. Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo). Adv. Drug Delivery Rev., Special issue on long circulating drugs and drug carriers, 1995, 16:127-139
C16	Papisov, MI. Theoretical considerations of RES-avoiding liposomes: molecular mechanics and chemistry of liposome interactions. Adv. Drug Delivery Rev. 1998, 32:119-138.
C17	Tomlinson et al. Polyacetal-doxorubicin conjugates designed for pH dependent degradation. Bioconjugate Chem., 2003, 14(6), 1096-1106
C18	Yurkovetskiy, A. et al. Biodegradable polyal carriers for protein modification. 29th Int. Symp. on Controlled Release of Bioactive Materials, 2002, Seoul, Korea. Controlled Release Society, Deerfield, IL, 2002; paper # 357
C19	Yurkovetskiy, A. et al. Biodegradable polyals for protein modification. Controlled Release Society's Winter Symposium, Salt Lake City, Utah, 2003
C20	Yurkovetsky, A. et al., Fully Degradable Hydrophilic Polyals for Protein Modification. Biomacromolecules 2005, 6, 2648-2658
C21	Zalipsky et al. Eur. Polym. J. (1983), Vol. 19, No. 12, p. 1177-1183

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

4597783v 1	Date Considered
---------------	--------------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,334
				Filing Date	October 27, 2005
				First Named Inventor	Mikhail I. Papisov
				Art Unit	1626
				Examiner Name	Chu, Yong Liang
Sheet	3	of	3	Attorney Docket Number	0492479-0041 (MGH 2170 US)

considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

4597783v 1		Date Considered	
---------------	--	--------------------	--